Introduction
The survival of patients with HIV infection dramatically improved after the introduction of highly active antiretroviral therapy (HAART) [1] . Opportunistic infections that once typified the course of HIV infection and led to shortened survival are rare. However, certain AIDS defining and non-AIDS defining cancers continue to be a major source of mortality [2] . For example, the incidence of Hodgkin's lymphoma and non-Hodgkin's lymphoma (NHL) is increased in HIV-infected patients compared to the general population. AIDS-related lymphomas are typified by an advanced stage at presentation and an aggressive clinical course [3] .
The treatment of AIDS-related non-Hodgkin's lymphoma also changed after the introduction of HAART. What was once the standard approach of low-dose chemotherapy was supplanted by more aggressive therapy used in HIV-negative patients such as R-CHOP. Further-more, the remission rates that are seen when R-CHOP is combined with antiretroviral therapy approach those of HIV-negative patients [4] . Hence, we are reaching an era where the standard treatment of HIV-related lymphomas mirrors that of HIV-negative patients. Therefore, it is not surprising that more aggressive therapies such as high-dose chemotherapy and stem cell transplantation have been explored in the post-HAART era. This review will highlight some of the recent studies of autologous and allogeneic stem cell transplantation and discuss the future potential of hematopoietic stem cell transplantation in HIV-positive patients.
who was on zidovudine and zalcitabine for antiretroviral therapy. The patient was treated with BEAM (BCNU, Etoposide, Cytarabine, Melphalan) chemotherapy for relapsed lymphoma. The posttransplant course was characterized by multiple opportunistic infections including cytomegalovirus viremia, mycobacterium pneumonia, and cryptosporidiosis. Thus, this initial experience confirmed the concerns that the immune dysfunction conferred by the HIV infection would greatly increase risk of infection. Nonetheless, it also demonstrated the feasibility of mobilizing stem cells and successful engraftment in the bone marrow milieu of active virus.
In the post-HAART era, French investigators initiated a larger trial [6] . Their study included patients with refractory or relapsed lymphoma, seven out of the eight had undetectable viral loads at study entry. Conditioning regimens were either radiation-based or chemotherapy alone. Four out of the eight were alive and in complete remission at the time of reporting, three died of lymphoma within the first 6 months post-ASCT and one died of an opportunistic infection. The study, therefore, demonstrated that in the HAART era, the mortality due to infection was greatly reduced but that control of the underlying lymphoma remained the challenge.
The City of Hope experience included patients with less advanced lymphoma and excluded chemotherapy refractory patients [7] . The initial series comprised 20 patients with either Hodgkin's lymphoma or NHL. All patients were on HAART and were required to have HIV viral loads less than 10 000 by RT PCR. The majority of patients received a chemotherapy-based conditioning of CBV (cyclophosphamide, BCNU, etoposide). Engraftment times were similar to HIV-negative patients, except for one patient who had delayed engraftment until day 23. This patient engrafted only after the discontinuation of the zidovudine that was part of his antiretroviral therapy. Although all attempts possible were made to continue antiretroviral therapy throughout the transplant period, in reality only nine of the 20 were able to tolerate it. The others had either nausea or mucositis that prevented good tolerance of oral medication. Progressionfree survival (PFS) was superior to the French series likely due to the inclusion of only chemosensitive patients. At the time of initial reporting the PFS was 85% and overall survival (OS) 81%. The cohort has expanded to 28 patients and with a median of 41 months follow-up the PFS remains high at 78%. In addition, transplant-related mortality was low and no patient succumbed to an opportunistic infection.
The Italian cooperative group on AIDS and tumors (GICAT) recently reported the long-term results on 50 patients with HIV and relapsed or refractory lymphoma [8] . Forty-six patients were already on HAART, two started at the time of study enrollment and two at the time of stem cell mobilization. Interestingly, in contrast to the City of Hope eligibility, no viral load criteria were included, although CD4 cell counts more than 100 cells/ml before first-line chemotherapy were required. Hence, the viral loads at study entry ranged from 204 to 750 000 copies/ml. Of note, 13 patients withdrew before stem cell collection: two because of toxic death, 13 due to progressive disease, and one due to patient refusal. Ultimately, 27 patients underwent stem cell transplantation. Of these, seven temporarily suspended HAART, some for similar reasons to the City of Hope experience, mucositis, and others for hepatoxicity. Three-year PFS for the patients who proceeded to transplant was also similar at 76.3%. Multivariate analysis for prognostic factors for survival showed that marrow involvement, performance status less than 2 and CD4 cell count below 100 cells/ml were significant. An EBMT retrospective multicenter trial of 68 patients from 20 institutions has been recently published. At the time of transplant 16 patients were in first compete remission (CR), 44 had more advanced disease including eight patients with chemorefractory disease. Relapse or progression occurred in 29.5% of patients. Analysis of prognostic factors demonstrated that histology other than diffuse large cell lymphoma, the use of more than two pre-ASCT treatment lines, and not being in CR at the time of transplant were significantly associated with a higher risk of post-ASCT relapse [9 ] .
Another multicenter trial, this time from the United States AIDS malignancy consortium had somewhat inferior results to the Italian and City of Hope experience [10] . Initially 27 patients were enrolled and ultimately 20 went to transplant. The viral load allowed for study entry was much higher than the City of Hope trial at 110 000 copies/ml. However, this did not seem to have much impact in regards to early transplant-related complications. However, long-term outcome was inferior to the European and the City of Hope results, with eventfree survival 49.5% and OS 74.4%. It is unclear whether this is due to patient selection in regards to lymphoma status or due to poorer control of the underlying HIV infection or due to the lower intensity of the busulfanbased conditioning regimen that was used.
Case-control studies have been performed to further delineate the effects of HIV status on transplant outcome for HIV-related lymphomas. A retrospective study from the EBMT compared 53 HIV-positive lymphoma patients who underwent transplant with controls matched for histology, nonage-adjusted IPI, and disease status at transplant [11 ] . In addition, three optional criteria of age at transplant, year and country of transplant were considered. Median follow-up was 30 months. OS was 61.5% (95% CI 47-76) for HIV-positive patients and 70% for controls (P ¼ NS). There was a trend toward delay in platelet engraftment posttransplant in the HIV cohort. It is unclear whether this related to the higher use of GCSF in that group or to antiretroviral therapy or to chronic HIV infection. A nonstatistically significant difference in nonrelapse mortality was seen in the HIV cohort, primarily due to the higher rate of bacterial infections. Interestingly, although there was not a difference in relapse rates between groups, there was a favorable tendency for lower rates in the HIV lymphoma group. This same trend was seen in the City of Hope case-control series. In that series 29 HIV-positive patients were compared with HIVnegative NHL patients. Two-year disease-free survival was 76% for HIV-positive patients versus 56% for controls (P ¼ NS) (unpublished data).
Future prospective studies will address the potential reasons for this improved outcome in the HIV-positive patient. Some of the possibilities include the benefits of HAART chemotherapy. In the conventional chemotherapy setting, HIV lymphoma responders to HAART had improved survival [12] . Other theories are that the transplant procedure itself may introduce perturbations in the HIV virus such as depletion in the HIV reservoir by the high-dose chemotherapy. Genotypic status of the patient may also influence outcome. The presence of the CCR5delta 32 gene mutation in early studies has been shown to be protective against the risk of developing lymphoma [13] . In our initial review of the genotypic status of our HIV ASCT patients, we found approximately 40% of our patients were heterozygous for the delta 32 gene mutation (unpublished data). A national trial of ASCT for HIV lymphoma will be conducted through the BMT CTN network. As part of this trial, the genotypic status of patients will be evaluated and we will prospectively determine if this can be correlated with disease-free survival. Correlative studies will also evaluate the HIV viral reservoir before and after transplant.
Allogeneic transplantation
Allogeneic hematopoietic stem cell transplantation poses a greater challenge due to the need for chronic immunosuppression in an already immunosuppressed patient. Solid organ transplantation paved the way for stem cell transplantation [14] . The solid organ transplants laid to rest some of the concerns about immunosuppression. The underlying HIV infection was able to be controlled if patients remained on antiretroviral therapy. Drug interactions due to cytochrome P450 inhibition by certain antiretrovirals were managed by dose adjustments of calcineurin inhibitors. Now our extensive experience with autologous hematopoietic stem cell transplants in HIV-positive patients has demonstrated that HIV infection did not delay engraftment times as long as myelosuppressive medications such as azidothymidine are avoided. Hence, one can anticipate similar engraftment times in the allogeneic setting. The pattern of immune recovery remains unknown. For example, in the HIV-negative allogeneic transplant, T cell recovery is first with CD8 þ cells, CD4 þ recovery generally can take up to 6 months [15] . A series of two HIV-positive patients who underwent nonmyeloablative transplant at Fred Hutchinson Research Center demonstrate some of the potential of allogeneic hematopoietic stem cell transplant in regards to HIV immune responses [16] . The two patients underwent a preparative regimen of fludarabine and 200 cGy total body irradiation. They received HLA-matched peripheral blood stem cells from an HLA-matched sibling or unrelated donor. HAART was continued throughout the transplant, although adjustments in HAART were made to avoid potential drug interactions. Reconstitution of CD4 and CD8 subsets was in keeping with other nonmyeloablative transplants. Further studies were done to see if the new HIVnaive donor cells could target HIV epitope specificities. The pattern of specificities of posttransplantation donor cells was different from pretransplant patterns in that new HIV-1-specific CD8 þ T cell responses were generated posttransplant. In the patient who achieved full donor chimerism, there was a loss of detectable proviral DNA that suggests that the pool of latently infected lymphocytes died out after transplantation. Hence, this experience was suggestive that allogeneic transplantation may have two-fold benefits.
Larger studies will need to be done to demonstrate if the benefits of allogeneic transplant can be sustained in the myeloablative setting with its attendant potential higher mortality. The largest series was a retrospective study of 30 patients transplanted between 1987 and 2003 from the EBMT [17] . The relevance of this study is limited by the fact that HAART was not available till after 1996. The transplant-related mortality was higher than in the HIVnegative transplant setting at 46%. Though, four of the eight patients in the post-HAART era survived versus two of 22 patients in the pre-HAART era.
Allogeneic transplantation for HIV infection
The most intriguing aspect of allogeneic hematopoietic stem cell transplantation is its potential to also control HIV infection. A case report in the New England Journal of Medicine demonstrated this point. A German patient with acute myelogenous leukemia underwent allogeneic stem cell transplantation from an HLA-matched unrelated donor who was homozygous for the CCR5 for the delta 32 deletion [18 ] . HAART was administered until day 1. The patient relapsed at day 332 and underwent a second transplant from the same donor with single dose TBI conditioning. Despite the absence of HAART, there was no rebounding of the HIV viral load posttransplant. The investigators went further and also looked for the HIV virus in compartments that can harbor the virus in the absence of detectable serum virus. The intestinal lamina propria is one important reservoir. In the patient rectal biopsy did reveal that CCR5-producing macrophages were still present in the intestinal mucosa which were, therefore, of host origin. But despite this, the HIV-1 DNA could not be detected in the rectal mucosa. Immunologic studies demonstrated a loss of anti-HIV virusspecific interferon Gamma producing T cells. This was suggestive that HIV antigen stimulation was not present after the transplant. Although the patient had non-CCR5 tropic X4 variants of the virus as well, his HIV viral load remained undetectable. After nearly 2 years of follow-up, the patient's CD4 cell count has returned to normal levels with all cells demonstrating the homozygous CCR5deleted gene.
Ideally, one would envision combining the benefits of the transplantation of cells with the CCR5 gene mutation but without the risks of allogeneic stem cell transplantation. One way to get this 'best of both worlds' would be the transplantation of autologous stem cells that were genetically modified to be CCR5 negative. We have conducted two trials at the City of Hope with this approach. The most recent used a lentivirus-based system to transduce stem cells with a combination of three forms of anti-HIV RNA. This included RNAi in the form of short-hairpin RNA targeted to an exon in HIV-1 tat/rev, a decoy for the HIV tat reactive element and a ribozyme that targets the host cell CCR5 chemokine receptor. Four patients with AIDS-related lymphoma were transplanted with autologous lentiviral-transduced modified stem cells and unmanipulated stem cells after high-dose chemotherapy. All patients engrafted and demonstrated low levels of genetically modified cells [19] . Future trials will address how to increase levels of engraftment of the genetically modified stem cells. Ideally this would then allow patients to also discontinue HAART.
Conclusion
The barrier of HIV infection as an impediment to transplant has been broken. Multiple studies have now demonstrated that ASCT can be performed safely in patients with underlying HIV infection and that the procedure may lead to durable remissions in patients with high-risk AIDS-related lymphomas. A large consortium-based trial of ASCT through the BMT CTN (clinical trials network) will open later this year. This trial will also encompass correlative studies evaluating the HIV reservoir, immunologic recovery, and pharmacokinetic interactions with antiretroviral therapy and chemotherapy. In addition, another BMT CTN ASCT trial for lymphoma in HIV-negative patients will serve as a retrospective historical control arm. Allogeneic stem cell transplantation remains a higher hurdle to overcome. There are no large studies to support this approach yet and the largest retrospective series is hindered by the fact that most of the patients were in the pre-HAART era. On the contrary, the Hutter experience of allogeneic stem cell transplantation with a CCR5-negative donor shows us a glimpse of the future where transplant will be used for control of malignancy and HIV infection.
